Event Date/Time: Apr 30, 2012
End Date/Time: May 01, 2012
The field of antibodies directed against cancer is burgeoning and this is a huge growth area due to the success of drugs already on the market. There still remain a number of challenges that include reducing immunogenicity, improving the targeting in solid tumors, and increasing the ability to kill cancer cells. The pre-clinical and clinical results of recent new constructs will be shared, and the changes in regulation of antibodies will be reviewed. The latest new approaches will be compared to more established techniques for filling the pipeline with future best-in-class drugs.